News


Combining Plasma Screening with Genetic Screening Helps ID Targets

For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits.

This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician’s ability to identify disease susceptibility in individuals and populations. This advance is published in the February 2013 issue of the journal GENETICS, Bethesda, Md.

“We hope that combining genome-wide with proteome-wide screening of blood plasma will aid in the identification of molecular disease mechanisms,” says Daniel Teupser, MD, a researcher involved in the work from the Institute of Laboratory Medicine at Ludwig-Maximilians-University, Munich, Germany. “The methodology is applicable to many frequent diseases such as diabetes, cardiovascular disease or cancer and might accelerate identification of novel diagnostic and therapeutic targets.”

Mass spectrometry has already been adapted for clinical applications, and plasma is often the target because of it easy accessibility. Since plasma comes in contact with most tissues, it often mirrors metabolism and disease. This study pioneers a promising approach to identify novel disease-associated proteins, which could provide novel diagnostic or therapeutic targets of disease.

“Gene variants are now easy to identify, so what’s become limiting is the traits — the phenotype — to link to those variants. This study goes a long way to opening up that bottleneck. The high-throughput screening the authors describe holds tremendous promise for finding diagnostic markers and therapeutic targets of disease,” said Mark Johnston, editor-in-chief of the journal GENETICS.

[Source: Genetics Society of America]

 

Genetics Society of America